These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 11713038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P.
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [Abstract] [Full Text] [Related]

  • 4. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
    Wakatsuki M, Suzuki Y, Nakamoto S, Ohno T, Ishikawa H, Kiyohara H, Kiyozuka M, Shirai K, Nakayama Y, Nakano T.
    J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
    [Abstract] [Full Text] [Related]

  • 5. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T.
    Cancer; 1997 May 01; 79(9):1647-55. PubMed ID: 9128978
    [Abstract] [Full Text] [Related]

  • 6. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
    Kainz C, Sliutz G, Mustafa G, Bieglmayr C, Koelbl H, Reinthaller A, Gitsch G.
    Gynecol Oncol; 1995 Mar 01; 56(3):402-5. PubMed ID: 7535720
    [Abstract] [Full Text] [Related]

  • 7. Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer.
    Brockmann JG, St Nottberg H, Glodny B, Sprakel B, Senninger N.
    Anticancer Res; 2000 Mar 01; 20(6D):4899-904. PubMed ID: 11332443
    [Abstract] [Full Text] [Related]

  • 8. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Mar 01; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 9. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
    Inal E, Laçin M, Asal K, Ceylan A, Köybaşioğlu A, Ileri F, Uslu SS.
    Kulak Burun Bogaz Ihtis Derg; 2004 Mar 01; 12(1-2):23-30. PubMed ID: 16010093
    [Abstract] [Full Text] [Related]

  • 10. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J, Wójcik E, Radkowski A, Kolodziejski L, Stasik Z.
    Anticancer Res; 2000 Mar 01; 20(6D):5035-40. PubMed ID: 11326663
    [Abstract] [Full Text] [Related]

  • 11. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
    Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D.
    Cancer; 1999 Mar 01; 85(5):1018-25. PubMed ID: 10091783
    [Abstract] [Full Text] [Related]

  • 12. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
    Tsai SC, Kao CH, Wang SJ.
    Neoplasma; 1996 Mar 01; 43(1):27-9. PubMed ID: 8843956
    [Abstract] [Full Text] [Related]

  • 13. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
    Molina R, Filella X, Augé JM, Bosch E, Torne A, Pahisa J, Lejarcegui JA, Rovirosa A, Mellado B, Ordi J, Biete A.
    Anticancer Res; 2005 Mar 01; 25(3A):1765-71. PubMed ID: 16033097
    [Abstract] [Full Text] [Related]

  • 14. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Van de Vijver MJ, Fleuren GJ, Trimbos JB.
    Gynecol Oncol; 2000 Apr 01; 77(1):164-70. PubMed ID: 10739706
    [Abstract] [Full Text] [Related]

  • 15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Apr 01; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 16. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
    Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fateh-Moghadam A.
    Anticancer Res; 1996 Apr 01; 16(5B):3117-24. PubMed ID: 8920778
    [Abstract] [Full Text] [Related]

  • 17. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx.
    Alkotyfan K, Wiegand S, Müller HH, Windfuhr JP, Werner JA, Sesterhenn AM.
    Anticancer Res; 2010 Jun 01; 30(6):2291-6. PubMed ID: 20651382
    [Abstract] [Full Text] [Related]

  • 18. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
    Tai CJ, Liu FY, Liang JA, Yang SN, Tsai MH, Kao CH.
    Anticancer Res; 2002 Jun 01; 22(6B):3793-6. PubMed ID: 12552995
    [Abstract] [Full Text] [Related]

  • 19. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY.
    Int J Oral Maxillofac Surg; 2007 Mar 01; 36(3):230-4. PubMed ID: 16965897
    [Abstract] [Full Text] [Related]

  • 20. CYFRA 21-1 serum analysis in patients with esophageal cancer.
    Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ.
    Clin Cancer Res; 2000 Nov 01; 6(11):4249-52. PubMed ID: 11106239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.